BioMarin Pharmaceutical Inc. (FRA:BM8)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
VOXZOGO Revenue	862.03M	735.09M	469.88M
VOXZOGO Revenue Growth	17.27%	56.44%	177.83%
VIMIZIM Revenue	777.62M	739.78M	701.05M
VIMIZIM Revenue Growth	5.11%	5.53%	5.62%
NAGLAZYME Revenue	475.18M	479.58M	420.29M
NAGLAZYME Revenue Growth	-0.92%	14.11%	-5.30%
PALYNZIQ Revenue	408.40M	355.05M	303.92M
PALYNZIQ Revenue Growth	15.03%	16.82%	19.17%
ALDURAZYME Revenue	198.16M	183.89M	131.25M
ALDURAZYME Revenue Growth	7.76%	40.11%	2.20%
BRINEURA Revenue	184.73M	169.08M	161.89M
BRINEURA Revenue Growth	9.25%	4.44%	4.90%
KUVAN Revenue	104.52M	120.90M	180.77M
KUVAN Revenue Growth	-13.55%	-33.12%	-20.57%
ROCTAVIAN Revenue	33.44M	26.07M	3.49M
ROCTAVIAN Revenue Growth	28.29%	647.09%	-
Total Net Product Revenue	3.04B	2.81B	2.37B
Total Net Product Revenue Growth	8.35%	18.41%	16.19%
Royalty and Other Revenue	49.93M	44.47M	46.69M
Royalty and Other Revenue Growth	12.28%	-4.75%	-13.56%
Revenue (Other)	-33.44M	-26.07M	-3.49M
Revenue (Total)	3.09B	2.85B	2.42B
Revenue (Total) Growth	8.41%	17.97%	15.42%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Royalty and Other Revenue	49.93M	44.47M	46.69M
Royalty and Other Revenue Growth	12.28%	-4.75%	-13.56%
United States Revenue	1.06B	924.81M	771.31M
United States Revenue Growth	14.32%	19.90%	12.72%
Europe Revenue	889.18M	829.03M	669.33M
Europe Revenue Growth	7.26%	23.86%	2.82%
Latin America Revenue	387.18M	378.08M	332.44M
Latin America Revenue Growth	2.41%	13.73%	24.60%
Rest of World Revenue (Pre-Q3 2024)	-	-	468.21M
Rest of World Revenue (Pre-Q3 2024) Growth	-	-	50.28%
Rest of World Revenue (Post-Q2 2024)	512.34M	493.63M	468.21M
Rest of World Revenue (Post-Q2 2024) Growth	3.79%	5.43%	50.28%
Revenue (Other)	198.16M	183.89M	131.25M
Revenue (Total)	3.09B	2.85B	2.42B
Revenue (Total) Growth	8.41%	17.97%	15.42%

Updated Sep 30, 2025. Data Source: Fiscal.ai.